Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
about
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimenBiomarkers in triple negative breast cancer: A reviewTriple-negative breast cancer: is there a treatment on the horizon?The differences in ultrasound and clinicopathological features between basal-like and normal-like subtypes of triple negative breast cancer.Metaplastic breast carcinomas are basal-like tumours.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients.microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancersExpression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer.LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort studyExpression of the embryonic stem cell marker SOX2 in early-stage breast carcinomaEstrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.Treatment options for patients with triple-negative breast cancerTopo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.Basal-like phenotype in a breast carcinoma case series from Sudan: prevalence and clinical/pathological correlations.Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancerMYC and Breast Cancer.Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.The changing role of pathology in breast cancer diagnosis and treatment.Management options in triple-negative breast cancerSignificance of rat mammary tumors for human risk assessment.Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy.Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survivalCD44 Promotes Epithelial Mammary Gland Development and Exhibits Altered Localization during Cancer ProgressionMolecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China.Basal breast cancer: a complex and deadly molecular subtypeDemystifying basal-like breast carcinomasBasal-like breast cancer: molecular profiles, clinical features and survival outcomesA comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.Distinct effects of β1 integrin on cell proliferation and cellular signaling in MDA-MB-231 breast cancer cells.Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-upInternational Web-based consultation on priorities for translational breast cancer research.Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer.
P2860
Q21092375-37AADF00-9B43-431D-851D-513688D38AA0Q26775094-3918331B-FD45-4854-ACD3-8D3FFB1D2B1EQ28077243-73630B88-6AC4-4DF9-BE97-8DF86D8F1633Q30417120-6CE858BE-2988-418C-AD22-A95CD6A64777Q33250228-8C9B74D7-8BDA-490B-88FC-EE18345412CEQ33291587-22011D22-8D55-4B28-BA28-501A95849B23Q33506542-E0D905DC-8150-4C0B-8B82-7F18A5347231Q33576814-BFEB3202-8B24-4EC8-9B8A-B83632C441A3Q33630849-9876E855-B0BB-4A0B-AAD3-B35AB1F3E914Q33740256-578A5D63-5895-4D34-9087-7E400562BE03Q33758934-6E6220EF-329A-47F3-ACA8-DCCEF7DBD75BQ33806378-7FC3221E-4330-487E-94B5-F7CB7003271CQ34088422-947B4EFF-0303-49F3-8B71-A6CF7B1EAA14Q34331406-0EFC68A7-5ABF-43CA-9C06-32567673708AQ34433737-05CEF46F-61A7-4DCF-AE07-98E4FC7260F0Q34512811-732D3F5B-30CA-4401-9FA8-D25D4B7ABA0DQ34582473-F9B5E516-D132-4ABF-873C-BA62B2554471Q34972381-0FC649A2-EDB0-4CCA-BA76-E243D5DC069DQ35010102-BD71A520-93C6-4211-BCF7-C37AF9422E77Q35042972-61EEA690-FEF2-4B8D-8063-59D6E0C533A7Q35082260-F6B9A7CF-25A2-406D-B227-21D27EB650C8Q35155460-35B7FCD4-FA9C-4908-AAA2-A82EF0CD8B64Q35174533-A0D5C36E-826A-47AA-99A1-140E0A664444Q35179485-1FDB3AB9-299F-4BF6-8FA3-BB6B163828B8Q35549438-E3EA2082-9669-458C-8CF6-23F8EF5B0368Q35558988-6F2EDFF3-BADA-44F3-ABF6-85E7F403E0FAQ35602598-DA083CF4-655E-490C-8F43-CEFAE68F8D39Q35749393-4D3E10AF-3DA6-4400-BC78-32FCAE2DF63AQ35749421-D7202136-FBAC-4B36-9ECC-0F3A7E3DA565Q35755182-A10B8D39-6F63-4F4F-B27C-2C6099E85AC0Q35799667-155CEFA7-BDB5-4734-A20A-A2BAA06355CFQ35909551-910B91C1-411A-4AEB-8399-1B664EFFA60AQ35931900-6E8A285E-7B68-4BE8-BF4F-D93C8429BDC3Q36172507-F5CCA471-9A60-420F-9EC9-62A5CFAFCD87Q36325873-69F3DDF3-B0D4-4341-B86E-98FB5099786AQ36369621-AF4B4E42-B1B8-4A9C-B1B7-C1FECD6E0BF7Q36427883-F5450A1D-7C58-4397-836F-9EA72325747BQ36442340-554F7228-543F-451E-B5F8-5B2D286CF411Q36465302-B000B731-CAA0-43EE-829C-E7B984C33F9CQ36473913-FA0F80DB-F7E6-4F8D-B895-55515FAED5C4
P2860
Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
@ast
Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
@en
type
label
Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
@ast
Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
@en
prefLabel
Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
@ast
Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
@en
P2093
P2860
P356
P1476
Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
@en
P2093
P2860
P304
P356
10.1136/JCP.2005.033043
P407
P577
2006-03-23T00:00:00Z